Form 4: Lyell CFO Sells Shares for Tax Obligations
Insider Transaction Report
Lyell Immunopharma's Chief Financial Officer, Charles W. Newton, sold shares to cover tax withholding obligations from vested restricted stock units.
Summary
- Charles W. Newton, Chief Financial Officer of Lyell Immunopharma, Inc. (LYEL), reported transactions involving the company's common stock.
- On August 11, 2025, 131 shares were sold at a weighted average price of $10.526 per share, with the sale price ranging from $10.045 to $11.00.
- On August 12, 2025, an additional 136 shares were sold at a weighted average price of $10.338 per share, with the sale price ranging from $10.120 to $10.415.
- Both sales were automatic transactions to cover tax withholding obligations arising from the settlement of vested restricted stock units.
- As of August 12, 2025, Charles W. Newton directly beneficially owned 8,759 shares of common stock.
- An additional 10,000 shares are indirectly beneficially owned through The Charles & Lisa Newton Living Trust, where Mr. Newton serves as co-trustee and co-grantor.
- All share amounts and prices reported reflect a 1-for-20 reverse stock split effected by Lyell Immunopharma on May 30, 2025.
- The direct beneficial ownership includes 390 shares acquired on May 18, 2025, under the Issuer's 2021 Employee Stock Purchase Plan.
Sentiment
Score: 5
Explanation: The filing reports routine, non-discretionary insider sales for tax withholding purposes, which is generally considered neutral in terms of market sentiment.
Positives
- The vesting of restricted stock units indicates compensation for the Chief Financial Officer, which is a positive for the individual's remuneration.
Future Outlook
NA
Industry Context
This filing is a routine insider transaction report and does not provide information directly related to broader industry trends or competitors.
Stakeholder Impact
- Shareholders: Minimal direct impact as the sales are small, routine, and non-discretionary for tax purposes, not indicative of a change in management's confidence.
- Employees: No direct impact beyond the reporting person's compensation.
Key Dates
| Date | Description |
|---|---|
| 05/18/2025 | Acquisition of 390 shares under the Issuer's 2021 Employee Stock Purchase Plan. |
| 05/30/2025 | Issuer effected a 1-for-20 reverse stock split of its common stock. |
| 08/11/2025 | Transaction date for sale of 131 shares to cover tax withholding from vested restricted stock units. |
| 08/12/2025 | Transaction date for sale of 136 shares to cover tax withholding from vested restricted stock units. |
| 08/13/2025 | Date of filing signature. |
Keywords
Lyell Immunopharma, LYEL, Form 4, Insider Trading, Stock Sale, CFO, Restricted Stock Units, Reverse Stock Split
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.